Anti-lymphoma application of morusin

By using Sancin as an anti-lymphoma drug, inhibiting lymphoma cell proliferation and inducing cell apoptosis, solving the toxic side effects, drug resistance and economic problems of existing treatment methods, providing a safe, economical and efficient treatment Solution, suitable for large-scale applications.

CN118976022APending Publication Date: 2024-11-19FUDAN UNIV SHANGHAI CANCER CENT
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411313881.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-20
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The existing lymphoma treatment methods have problems such as toxic side effects, drug resistance, high cost and limited treatment options, especially the lack of effective means for patients with relapse or routine treatment ineffectiveness, and the insufficient purity and stability of Chinese medicine extracts affect the therapeutic effect. .

Method used

Soncin as an anti-lymphoma drug, effectively administered by inhibiting lymphoma cell proliferation, inducing cell apoptosis, preventing cell cycle, improving drug sensitivity, and using a variety of dosage forms such as capsules, tablets, liquids, etc., combined with Common Chinese herbal medicine extraction to reduce costs.

Benefits of technology

Sancin showed good anti-resistant B-cell lymphoma activity in vitro and in vivo, with low toxicity and significant therapeutic effects, prolonging the effectiveness of chemotherapy drugs, and providing a novel, efficient, safe and economical therapeutic option. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118976022A_ABST
    Figure CN118976022A_ABST
Patent Text Reader

Abstract

The invention relates to an anti-lymphoma application of morusin, and provides an application of morusin in preparation of an anti-lymphoma drug, and the lymphoma can be drug-resistant lymphoma. The anti-lymphoma drug can be a drug for inhibiting lymphoma cell proliferation, a drug for activating expression of lymphoma cell apoptosis related protein, a drug for increasing drug sensitivity of lymphoma cells to anti-tumor drugs and the like. Compared with the prior art, the morusin provided by the invention has a multi-target effect on lymphoma cells, and shows good activity of resisting drug-resistant B cell lymphoma cells in vitro and in vivo, and experiments show that the morusin can inhibit cell proliferation, induce cell apoptosis, induce cell cycle arrest and reduce cell drug resistance, and has a good application prospect. The validity period of the anti-tumor medicine is prolonged.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, in particular to anti-lymphoma use of sansin. Background Art

[0002] Existing treatments for lymphoma mainly include chemotherapy, radiotherapy, targeted therapy, and immunotherapy, but these methods have many limitations: (1) Chemotherapy and radiotherapy have significant toxic side effects on normal cells, causing patients to experience side effects such as nausea, vomiting, hair loss, and bone marrow suppression, which seriously affects their quality of life. (2) Cancer cells are prone to drug resistance, which leads to a gradual decline in the treatment effect or even ineffectiveness. (3) Although targeted therapy drugs have certain selectivity, long-term use can also lead to drug resistance. They are also expensive and have a heavy economic burden, limiting their widespread application. (4) Immunotherapy has a low response rate and may cause immune-related adverse reactions. (5) Existing treatment options are limited and expensive, and cannot cover the needs of all patients, especially for patients who relapse or fail to respond to conventional treatments. There is a lack of effective treatments.

[0003] At present, research has been conducted to extract active ingredients from traditional Chinese medicine or other natural plants, and then use them for the treatment of tumors. For example, extracts of Chinese medicines such as Astragalus, Ganoderma lucidum, and Sophora flavescens have been used for anti-tumor treatment and have shown certain effects in in vitro experiments and animal models. Monomeric compounds isolated from Chinese medicinal materials, such as vincristine, camptothecin, and paclitaxel, have been shown to have significant effects in the treatment of various tumors. These monomeric compounds exert anti-tumor effects through specific biological mechanisms, such as inhibiting tumor cell proliferation, inducing cell apoptosis, or preventing angiogenesis. Sansin has attracted much attention due to its significant anti-tumor activity. Studies have shown that Sansin mainly promotes tumor cell apoptosis, effectively inhibits its proliferation and survival, and has a significant inhibitory effect on various cancer types such as breast cancer, colon cancer, glioma, and liver cancer. In addition, the anti-inflammatory and antioxidant properties of Sansin further enhance its anti-tumor activity, making it a potential anti-cancer candidate. However, lymphoma is a malignant tumor originating from the lymphatic system. Different tumors have different biological characteristics and molecular mechanisms, and their sensitivities to drugs also vary. Therefore, it is not yet clear whether sansin has anti-lymphoma activity.

[0004] The current extraction and purification processes of some Chinese herbal medicine extracts are relatively crude, which also affects the stability and effectiveness of the drugs. The low purity of the extracts may lead to unstable treatment effects and even cause adverse reactions. Many studies have only verified the anti-tumor activity of Chinese herbal medicine extracts in in vitro experiments, lacking comprehensive in vivo experimental data, resulting in the inability to fully verify the effectiveness and safety of the drugs in clinical applications, affecting their promotion and use. In addition, individual differences also lead to large differences in the effects of the same treatment on different patients. Existing treatment methods lack personalization and it is difficult to achieve precision treatment. Summary of the invention

[0005] The purpose of the present invention is to overcome the above-mentioned defects of the prior art and provide the anti-lymphoma use of sansin.

[0006] The purpose of the present invention can be achieved by the following technical solutions:

[0007] One of the technical solutions of the present invention is to provide the use of sansin in the preparation of anti-lymphoma drugs.

[0008] In some embodiments, the lymphoma is drug-resistant lymphoma.

[0009] In some embodiments, the lymphoma is a B-cell lymphoma.

[0010] In some specific embodiments, the anti-lymphoma drug is a drug that inhibits the proliferation of lymphoma cells, and the lymphoma cells include RL4RH cell line, Raji4RH cell line, SU-DHL-4 cell line, RIVA cell line, U2932 cell line, and RL cell line.

[0011] The drug for inhibiting the proliferation of lymphoma cells can be a drug that prevents lymphoma cells from entering the proliferation phase, leading to G1 phase tumor cell cycle arrest.

[0012] In some specific embodiments, the anti-lymphoma drug is a drug that activates the expression of apoptosis-related proteins in lymphoma cells.

[0013] In some specific embodiments, the lymphoma cell apoptosis-related proteins include Bax, TRADD, CASP9, MCL1, PIK3R2, SPTA1, and BIRC3.

[0014] In some specific embodiments, the anti-lymphoma drug is a drug that increases the drug sensitivity of lymphoma cells to anti-tumor drugs.

[0015] In some specific embodiments, the anti-tumor drugs include doxorubicin, rituximab, and cisplatin.

[0016] In some specific embodiments, the anti-lymphoma drug is a drug that increases the content of metabolites benzodiazepine compounds and flavonoid compounds in lymphoma cells.

[0017] In some specific embodiments, the anti-lymphoma drug is a drug that upregulates the expression of DAPK2, PXDNL, GSDMA, NLRP7, AGAP5, CDK1, and PTPN6 in lymphoma cells, or a drug that downregulates the expression of ATP1A4, IQGAP2, SNX15, SCD, HMGCS1, Trim25, ARPC18, and RPL19 in lymphoma cells.

[0018] The administration mode of the compound of the present invention or pharmaceutical composition is not particularly limited, and representative administration modes include (but are not limited to): oral, parenteral (intravenous, intramuscular or subcutaneous), and topical administration. Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) fillers or extenders, for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid; (b) binders, for example, hydroxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose, and acacia; (c) humectants, for example, glycerol; (d) disintegrants, for example, agar, calcium carbonate, potato starch or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) solubilizers, for example, paraffin; (f) absorption accelerators, for example, quaternary ammonium compounds; (g) wetting agents, for example, cetyl alcohol and glyceryl monostearate; (h) adsorbents, for example, kaolin; and (i) lubricants, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents.

[0019] Solid dosage forms such as tablets, pills, capsules, pills and granules can be prepared using coatings and shell materials, such as enteric coatings and other materials known in the art. They may contain opacifiers, and the release of the active compound or compounds in such compositions can be delayed in a certain part of the digestive tract. Examples of embedding components that can be used are polymeric substances and waxes. If necessary, the active compound can also be formed into microencapsulated form with one or more of the above-mentioned excipients.

[0020] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures. In addition to the active compound, the liquid dosage form may contain an inert diluent conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butylene glycol, dimethylformamide and oils, in particular cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil or mixtures of these substances, etc.

[0021] Besides such inert diluents, the composition may also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

[0022] Suspensions, in addition to the active compounds, may contain suspending agents such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methanol and agar, or mixtures of these substances, and the like.

[0023] Compositions for parenteral injection may include physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.

[0024] Dosage forms for topical administration of the compounds of the invention include ointments, powders, patches, sprays and inhalants. The active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants that may be required.

[0025] The compounds of the present invention can be administered alone or in combination with other pharmaceutically acceptable drugs.

[0026] Compared with the prior art, the present invention has the following beneficial effects:

[0027] (1) Sanosin has multi-target effects and exhibits good anti-resistant B-cell lymphoma cell activity both in vitro and in vivo. Experiments have shown that Sanosin can inhibit cell proliferation, induce cell apoptosis, induce cell cycle arrest and reduce cell resistance, and prolong the effective period of anti-tumor drugs such as conventional chemotherapy drugs.

[0028] In addition, since sansin has low toxicity and no obvious damage to normal cells, it fully demonstrates the significant effect and safety of sansin in fighting drug-resistant B-cell lymphoma. It is expected to overcome the limitations of existing technologies, meet clinical and market needs, and provide lymphoma patients with a novel, efficient, safe and economical option.

[0029] (2) Morinda citrinin is derived from the common Chinese medicinal material Morus alba bark, which has low extraction cost, high economic benefits and broad promotion potential, and is suitable for large-scale production and application. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 Sansin inhibits cell proliferation of drug-resistant B-cell lymphoma cell lines in vitro.

[0031] Figure 2 Sansin induces cell cycle arrest in drug-resistant B-cell lymphoma cell lines in vitro.

[0032] Figure 3 Sansin induces apoptosis in drug-resistant B-cell lymphoma cell lines in vitro.

[0033] Figure 4 Sansin inhibits cell proliferation and apoptosis of the drug-resistant B-cell lymphoma cell line RL4RH in nude mice.

[0034] Figure 5 Sanisin increases the chemosensitivity of drug-resistant B-cell lymphoma cell lines to doxorubicin.

[0035] Figure 6 A multi-omics approach was used to analyze the target molecules of sansin in drug-resistant B-cell lymphoma cell lines. DETAILED DESCRIPTION

[0036] The present invention is described in detail below in conjunction with the accompanying drawings and specific embodiments. This embodiment is implemented based on the technical solution of the present invention, and provides a detailed implementation method and specific operation process, but the protection scope of the present invention is not limited to the following embodiments.

[0037] In the following examples, unless otherwise specified, raw materials or processing techniques are conventional commercially available raw materials or conventional processing techniques in the art.

[0038] Human B-cell lymphoma-related cell culture:

[0039] Human B-cell lymphoma-related cell lines (SU-DHL-4, RIVA, Raji4RH, RL4RH, U2932 cell lines) were cultured in RPMI-1640 medium (MA0548, ) in a medium supplemented with 10% fetal bovine serum (Hyclone) and 1% penicillin-streptomycin (15140-122, Gibco TM ), and the culture conditions were 37°C and 5% CO2.

[0040] Sanxinsu is a conventional commercially available product, and its structure is as follows:

[0041]

[0042] Example 1: CCK8 cell proliferation inhibition experiment of the sansin of the present invention in vitro inhibiting cell proliferation of human drug-resistant B-cell lymphoma cell line:

[0043] 1000 human B cell lymphoma cells (SU-DHL-4, RIVA) and drug-resistant human B cell lymphoma cells (Raji4RH, RL4RH) were inoculated in 96-well plates, with 3 to 6 replicate wells in each group. Each well was treated with 2.5 to 5 μM sangsin monomer in a 37°C, 5% CO2 cell culture incubator for 96 to 120 hours. The control group was treated with solvent DMSO. CCK8 solution (MA0218, ) After incubation for 2 hours in the same environment, the OD value was measured and the cell survival rate was calculated, cell survival rate = OD value of the treatment group ÷ OD value of the control group × 100%.

[0044] result:

[0045] like Figure 1 As shown, Solvent represents the solvent DMSO control, and Morusin represents the Morusin experimental group.

[0046] Mulberry extract at a concentration of 5 μM significantly inhibited the cell proliferation of the SU-DHL-4 cell line, at a concentration of 5 μM significantly inhibited the cell proliferation of the RIVA cell line, at a concentration of 2.5 μM significantly inhibited the cell proliferation of the Raji4RH cell line, and at a concentration of 4 μM significantly inhibited the cell proliferation of the RL4RH cell line.

[0047] It can be seen that Sansin can significantly inhibit the cell proliferation of B-cell lymphoma cell lines and drug-resistant B-cell lymphoma cell lines.

[0048] Example 2: Cell cycle arrest of drug-resistant B-cell lymphoma cell lines induced by sanshin in vitro

[0049] Processing process of sansin monomer

[0050] 500,000 B cell lymphoma cells (SU-DHL-4) and drug-resistant B cell lymphoma cells (RL4RH) were inoculated in 25 mm culture dishes, with 2 to 3 replicates in each group. 10 μM concentration of sansin monomer was added to each well and treated in a cell culture incubator at 37°C and 5% CO2 for 24 hours. The control group was treated with solvent DMSO.

[0051] The cell cycle distribution was detected by flow cytometry, and the cell cycle and apoptosis detection kit (MA0334, ) instructions, the treated cells were fixed and stained, and the changes in the proportion of cells in the G0 / G1, S, and G2 / M phases were analyzed by flow cytometry.

[0052] result:

[0053] like Figure 2 As shown, Solvent represents the solvent DMSO control, and Morusin represents the Morusin experimental group.

[0054] Flow cytometric analysis of the cell cycle showed that treatment of SUDHL-4 and RL4RH cell lines with 10 μM sansin for 24 hours significantly downregulated the S phase and upregulated the G1 phase, indicating that the G1 / S phase transition process of the cells was blocked and cell proliferation was inhibited.

[0055] Example 3: Sancin of the present invention induces apoptosis of drug-resistant B-cell lymphoma cell lines in vitro.

[0056] (1) Annexin V-FITC / PI double staining method to detect the effect of sansin on apoptosis of B cell lymphoma cells

[0057] About 1 to 500,000 B cell lymphoma cells (SU-DHL-4) and drug-resistant B cell lymphoma cells (RL4RH) were inoculated in 25 mm culture dishes, with 2 to 3 replicates in each group. 10 μM concentration of sansin monomer was added to each well and treated in a cell culture incubator at 37°C and 5% CO2 for 24 hours. The control group was treated with solvent DMSO.

[0058] According to the cell cycle and apoptosis detection kit (MA0334, ) instructions, and the proportion of early and late apoptotic cells was analyzed by flow cytometry.

[0059] (2) Western blot detection of the effect of sansin on the expression of apoptosis-related proteins in B cell lymphoma cells

[0060] About 1 to 500,000 B-cell lymphoma cells (RIVA) and drug-resistant B-cell lymphoma cells (U2932, RL4RH) were inoculated in 25 mm culture dishes, with 2 to 3 replicates in each group. 10 μM concentration of sansin monomer was added to each well and treated in a cell culture incubator at 37°C and 5% CO2 for 24 hours. The control group was treated with solvent DMSO.

[0061] The B cell lymphoma cells treated with sansin and DMSO were lysed with RIPA buffer (Biyuntian, P0013B) to collect proteins, and PMSF (Biyuntian, ST505) was added within 5 minutes before use. The proteins were separated by 10% SDS-PAGE gel, transferred to the membrane (PVDF membrane), blocked, incubated with primary antibodies (GAPDH, proteintech, catalog number 60004-1-Ig; BCL-2, proteintech, catalog number 12789-1-AP; BAX, proteintech, catalog number 50599-2-Ig), incubated at 4°C overnight, washed with TBST solution 3 times, incubated with secondary antibodies for about 1 to 2 hours, and washed 3 times. The target protein was detected using chemiluminescence (ECL) method (Biyuntian, P0018S).

[0062] result:

[0063] Solvent represents the solvent DMSO control, and Morusin represents the Morusin experimental group.

[0064] like Figure 3 The results of flow cytometry detection of B cell lymphoma cell apoptosis shown in A and B indicate that after treatment of SUDHL-4 and RL4RH cell lines with 10 μM sansin for 24 hours, the death rate of lymphoma cell lines was significantly increased.

[0065] like Figure 3 As shown in C, Western blot results showed that 10 μM sansin significantly induced an increase in BAX expression and a decrease in BCL-2 expression in resistant B cell lymphoma cells.

[0066] Example 4: The sangsin of the present invention inhibits cell proliferation and apoptosis of the drug-resistant B-cell lymphoma cell line RL4RH in nude mice.

[0067] (1) Establishment of animal model:

[0068] Six-week-old nude mice were selected and 5×10 cells of drug-resistant RL4RH human lymphoma cell line were implanted in each mouse. 6 The cells were inoculated subcutaneously in nude mice to establish a transplanted tumor model.

[0069] (2) Drug administration:

[0070] A nude mouse transplant tumor model was selected. On the 5th day after subcutaneous tumor formation in nude mice, 12 animals were randomly divided into a DMSO solvent control group and a sansin (dose of 15 mg / Kg) treatment group.

[0071] Each group was given the drug by intraperitoneal injection 3 times a week for 10 consecutive days.

[0072] (3) Tumor volume measurement:

[0073] The tumor volume was measured every 2 days, and the volume change curve was plotted.

[0074] (4) Histological analysis:

[0075] After 10 days of Morusin and control treatment, the experiment was terminated, and tumor tissues were removed for immunohistochemical staining: Ki-67 staining was used to evaluate cell proliferation; TUNEL staining was used to observe cell apoptosis.

[0076] result:

[0077] Solvent represents the solvent DMSO control, and Morusin represents the Morusin experimental group.

[0078] like Figure 4 The volume change curve shown in A shows that starting from the 4th day after Morusin treatment, the tumor size of the Morusin-treated group was significantly smaller than that of the control group.

[0079] like Figure 4 B shows the tumor tissue. The experimental mice were killed on the 10th day after Morusin treatment, and the tumor tissues were separated and displayed in groups.

[0080] like Figure 4 The weight of tumor tissue shown in C shows that the weight of tumor tissue in the Morusin-treated group is significantly smaller than that in the control group.

[0081] like Figure 4 As shown in D, the Ki-67 proliferation marker molecule staining in the tumor tissue of the Morusin-treated group was significantly lower than that in the control group.

[0082] like Figure 4 E shows the cell apoptosis. The TUNEL apoptosis index of the tumor tissue in the Morusin-treated group was significantly higher than that in the control group.

[0083] Example 5: Sancin of the present invention increases the drug sensitivity of B cell lymphoma cell lines to doxorubicin

[0084] CCK8 cell sensitivity test:

[0085] 5000 B cell lymphoma cells (SU-DHL-4, RIVA) and drug-resistant B cell lymphoma cells (Raji4RH, RL4RH) were inoculated in 96-well plates, with 3 to 6 replicate wells in each group. Sancin monomer (according to the concentration gradient of 0 μM, 1.25 μM, 2.5 μM, 5 μM, 10 μM, 20 μM) with or without doxorubicin (Dox) (according to the concentration gradient of 0 μM, 0.0625 μM, 0.125 μM, 0.25 μM, 0.5 μM, 1 μM) was incubated in a cell culture incubator at 37°C and 5% CO2 for 48 to 72 hours, and CCK8 solution (MA0218, ) After incubation for 2 hours in the same environment, the OD value was measured and the cell survival rate was calculated, cell survival rate = OD value of the treatment group ÷ OD value of the control group × 100%.

[0086] result:

[0087] Solvent represented the solvent DMSO control, Morusin represented the Morusin experimental group, DOX represented the doxorubicin-treated experimental group, and DOX+Morusin represented the doxorubicin- and Morusin-treated experimental group.

[0088] like Figure 5 As shown in the figure, after treatment with doxorubicin (Dox) and Morusin, the cell viability of lymphoma cells decreased significantly. In particular, the cell viability of lymphoma cells treated with doxorubicin and Morusin decreased more significantly, indicating that there is a synergistic effect between the two.

[0089] Example 6: Multi-omics analysis of the target molecules of Sansinsu in B-cell lymphoma cell lines

[0090] Multi-omics analysis: 1×10 of human B-cell lymphoma cell line (RIVA) and drug-resistant human B-cell lymphoma cell line (RL4RH) were respectively 7 The cells were cultured in a 10 cm culture dish, and one well was set for each of the DMSO solvent control group and the sansin treatment group (10 μM). After treatment in a cell culture incubator at 37°C and 5% CO2 for 24 hours, the cell samples were collected according to the sample delivery requirements, and eukaryotic transcriptome, non-target metabolomics, and non-labeled quantitative proteomics (4D-Label Free-75min) were detected.

[0091] result:

[0092] Solvent represents the solvent DMSO control, and Morusin represents the Morusin experimental group.

[0093] like Figure 6The results of the non-target metabolomics analysis described in A showed that the contents of the metabolite derivatives Benzodiazepine (benzodiazepine compound) and the metabolite Flavonoids (flavonoid compound) after treatment with sangsin were significantly increased. According to relevant literature reports, these two metabolites may also have effects on RIVA and RL4RH cell lines, such as inducing cell death, inhibiting cell proliferation, affecting cell cycle, and enhancing sensitivity to radiotherapy and chemotherapy.

[0094] like Figure 6 The results of transcriptomic and proteomic integration analysis shown in B show that multiple molecules in drug-resistant RL4RH cells treated with sangsin were regulated, such as upregulated molecules including DAPK2, PXDNL, GSDMA, NLRP7, AGAP5, etc., while downregulated molecules included ATP1A4, IQGAP2, SNX15, SCD and HMGCS1, etc. This is consistent with the apoptosis and cell cycle regulation mentioned above.

[0095] like Figure 6 The results of non-labeled quantitative proteomics (4D-Label Free-75min) analysis shown in C show that after treatment with sangsin, Trim25, ARPC18, RPL19 and other protein molecules were down-regulated, while CDK1, PTPN6 and other molecules were up-regulated. This is consistent with the cell apoptosis and cell cycle regulation mentioned above.

[0096] The above description of the embodiments is to facilitate the understanding and use of the invention by those skilled in the art. It is obvious that those skilled in the art can easily make various modifications to these embodiments and apply the general principles described herein to other embodiments without creative work. Therefore, the present invention is not limited to the above embodiments, and improvements and modifications made by those skilled in the art based on the disclosure of the present invention without departing from the scope of the present invention should be within the scope of protection of the present invention.

Claims

1. Application of sansin in the preparation of anti-lymphoma drugs.

2. The use according to claim 1, wherein the lymphoma is drug-resistant lymphoma.

3. The use according to claim 1, characterized in that: The lymphoma is B cell lymphoma.

4. The use according to claim 1, characterized in that: The anti-lymphoma drug is a drug for inhibiting the proliferation of lymphoma cells, and the lymphoma cells include RL4RH cell line, Raji4RH cell line, SU-DHL-4 cell line, RIVA cell line, U2932 cell line, and RL cell line.

5. The use according to claim 1, characterized in that: The anti-lymphoma drug is a drug that activates the expression of apoptosis-related proteins in lymphoma cells.

6. The use according to claim 6, characterized in that: The lymphoma cell apoptosis-related proteins include Bax, TRADD, CASP9, MCL1, PIK3R2, SPTA1, and BIRC3.

7. The use according to claim 1, characterized in that: The anti-lymphoma drug is a drug that increases the sensitivity of lymphoma cells to anti-tumor drugs.

8. The use according to claim 7, characterized in that: The anti-tumor drugs include doxorubicin, rituximab and cisplatin.

9. The use according to claim 1, characterized in that: The anti-lymphoma drug is a drug that increases the content of metabolites, such as benzodiazepine compounds and flavonoid compounds, in lymphoma cells.

10. The use according to claim 1, characterized in that: The anti-lymphoma drug is a drug that upregulates the expression of DAPK2, PXDNL, GSDMA, NLRP7, AGAP5, CDK1, and PTPN6 in lymphoma cells, or a drug that downregulates the expression of ATP1A4, IQGAP2, SNX15, SCD, HMGCS1, Trim25, ARPC18, and RPL19 in lymphoma cells.

Citation Information

Patent Citations

  • Screening target, application and screening method of anti-tumor drugs

    CN112641947A

  • Application of small molecule compound in preparation of medicine for treating diffuse large B-cell lymphoma

    CN115212199A